<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480101</url>
  </required_header>
  <id_info>
    <org_study_id>LAIV-H7N9-01</org_study_id>
    <nct_id>NCT02480101</nct_id>
  </id_info>
  <brief_title>Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine</brief_title>
  <official_title>Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute of Influenza, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Experimental Medicine, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Institute of Influenza, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre phase I, double-blind placebo-controlled study to assess
      reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9)
      influenza vaccine in healthy male and female adults, 18 through 49 years of age .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immediate reactions</measure>
    <time_frame>2 hours</time_frame>
    <description>Immediate reactions occurring within two hours of administration of any dose, measured as observed by study staff or reported by the subject to study staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>Greater than two hours after administration of any dose of study vaccine or placebo through 6 days following any dose</time_frame>
    <description>Adverse events commonly associated with intranasal vaccination (solicited local and systemic reactions), measured as observed by study staff or reported by the subject to study staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in laboratory findings</measure>
    <time_frame>Days 3, 6 and 34</time_frame>
    <description>Abnormal laboratory findings from blood and urine specimens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>4 weeks of receipt of any dose</time_frame>
    <description>All SAEs during 56 days, as observed by study staff, reported by the subject to study staff, or noted by the subject on a diary card, including abnormal laboratory findings from blood specimens collected on Days 28 (pre-vaccination) and 56</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune responses</measure>
    <time_frame>Days 0, 28 and 56</time_frame>
    <description>Immune responses was parameterized as the proportion of subjects with at least a four-fold rise after each dose from baseline or as the mean titer after each dose in any of the following:
Serum hemagglutination inhibition (HAI) antibodies
Serum neutralizing antibodies
Serum immunoglobulin class A (IgA) or immunoglobulin class G (IgG) antibodies measured by enzyme-linked immunosorbent assay (ELISA)
Secretory IgA antibodies from the nasal mucosa detected in nasal wick specimens using ELISA
Secretory IgA antibodies in saliva specimens using ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus shedding</measure>
    <time_frame>Days 0-6 after each dose</time_frame>
    <description>Virus shedding with virus detected by real-time reverse transcriptase polymerase chain reaction rRTPCR in nasal swabs at any time point (at day of vaccination and daily during hospitalization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus stability</measure>
    <time_frame>Days 0-6 after each dose</time_frame>
    <description>Virus stability (virus detected and sequenced after inoculation into chicken eggs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellular immune responses (cytokine and T-cell)</measure>
    <time_frame>Days 0, 28 and 56</time_frame>
    <description>Cellular immune responses (cytokine and T-cell) was measured using isolated peripheral blood mononuclear cells (PBMCs) tested by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) assay.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>H7N9 LAIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>H7N9 live influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lyophilized purified allantoic fluid of chicken embryos with stabilizers</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9 live influenza vaccine</intervention_name>
    <description>H7N9 live influenza vaccine</description>
    <arm_group_label>H7N9 LAIV</arm_group_label>
    <other_name>LAIV H7N9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lyophilized purified allantoic fluid of chicken embryos with stabilizers</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legal male or female adult 18 through 49 years of age at the enrollment visit.

          -  Literate and willing to provide written informed consent.

          -  A signed informed consent.

          -  Free of obvious health problems, as established by the medical history and screening
             evaluations, including physical examination.

          -  Capable and willing to complete diary cards and willing to return for all follow-up
             visits

          -  Willing to comply with the rules of the isolation unit (including willing and able to
             take oseltamivir influenza antiviral medication, should that be recommended by a study
             physician).

          -  For females, willing to take reliable birth control measures through day 56.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any therapy within the previous
             three months or planned enrollment in such a trial during the period of this study.

          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to
             postpone receipt of such vaccines until four weeks after study completion.

          -  Practice of nasal irrigation on a regular basis within the past six months or has
             engaged in nasal irrigation within two weeks prior to enrollment.

          -  Recent history of frequent nose bleeds (more than 5 within the past year).

          -  Clinically relevant abnormal paranasal anatomy.

          -  Recent history (within the past month) of rhino or sinus surgery, or surgery for any
             traumatic injury of the nose.

          -  Current or recent (within two weeks of enrollment) acute respiratory illness with or
             without fever.

          -  Other acute illness at the time of study enrollment.

          -  Receipt of immune globulin or other blood products within three months prior to study
             enrollment or planned receipt of such products during the period of subject
             participation in the study.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             enrollment (for corticosteroids, this means prednisone or equivalent, 0.5 mg per kg
             per day; topical steroids are allowed, exclusive of nasal.)

          -  Participation in any previous trial of any H7 or H5 containing influenza vaccine.

          -  History of bronchial asthma.

          -  Hypersensitivity and allergy reactions after previous administration of any vaccine.

          -  History of wheezing after past receipt of any live influenza vaccine.

          -  Other AE following immunization (body temperature more than 40Â°C, collapse,
             non-febrile seizures, anaphylaxis), at least possibly related to previous receipt of
             any vaccine (not only influenza).

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein.

          -  Seasonal (autumnal) hypersensitivity to the natural environment.

          -  Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic,
             neurologic, psychiatric or renal functional abnormality, as determined by medical
             history, physical examination or clinical laboratory screening tests, which in the
             opinion of the investigator, might interfere with the study objectives. Subjects with
             physical examination findings or clinical laboratory screening results which would be
             graded 2 or higher on the AE severity grading scale will be excluded from entry into
             the study and will be excluded from receipt of dose two of study vaccine or placebo.

          -  History of leukemia or any other blood or solid organ cancer.

          -  History of thrombocytopenic purpura or known bleeding disorder.

          -  History of seizures.

          -  Known or suspected immunosuppressive or immunodeficient condition of any kind,
             including HIV infection.

          -  Known chronic HBV or HCV infection.

          -  Known tuberculosis infection or evidence of previous tuberculosis exposure.

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Claustrophobia or sociophobia.

          -  Pregnancy or lactation (a negative pregnancy test will be required before
             administration of study vaccine or placebo for all women of childbearing potential).

          -  Any condition that, in the opinion of the investigator, would increase the health risk
             to the subject if he/she participates in the study or would interfere with the
             evaluation of the study objectives.

          -  Allergic, including anaphylactic, reactions to the introduction of any vaccines in the
             subject's medical history (not only flu vaccine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larisa G Rudenko, MD PhD DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Experimental Medicine</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research Institute of Influenza, Russia</investigator_affiliation>
    <investigator_full_name>Oleg Kiselev</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>influenza vaccine pandemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

